Anti-Mouse CD120b (TNFR2) [Clone TR75-54.7] — Purified in vivo GOLD™ Functional Grade

Anti-Mouse CD120b (TNFR2) [Clone TR75-54.7] — Purified in vivo GOLD™ Functional Grade

Product No.: T254

[product_table name="All Top" skus="T254"]

- -
- -
Clone
TR75-54.7
Target
TNFR2
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Tumor Necrosis Factor Receptor II, p75, CD120b, TBPII, TNF-R75, TNFBR, TNFR2, TNFR80, p75TNFR
Isotype
IgG
Applications
B
,
ELISA Cap
,
FC
,
in vivo
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Armenian Hamster
Recommended Dilution Buffer
Immunogen
Purified Recombinant Mouse TNF R2
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Anti-Mouse CD120 recognizes Mouse CD120. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background
Tumor necrosis factor receptor II (TNF-RII) is present on most cell types1 and is considered to play a prominent role in stimulation by TNF-alpha. TNFRII proteins are expressed by hematopoietic cells including macrophages, neutrophils, lymphocytes, thymocytes and mast cells. It is expressed by a variety of other cell types including endothelial cells, cardiac myocytes and prostate cells.2
Antigen Distribution
Variety of cell types at low levels
Ligand/Receptor
TNF-α, LT-α (TNF-β)
Function
Apoptosis, NF-κB activation, inflammation, tumor necrosis, cell differentiation
NCBI Gene Bank ID
Research Area
Immunology
.
Innate Immunity

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone TR75-54.7 is widely used in vivo in mice for studies targeting mouse TNFR2 (CD120b), primarily to investigate antitumor immunity, tumor growth suppression, and immune modulation.

Key in vivo applications include:

  • Enhancing anti-tumor immunity and promoting immune responses against tumors, particularly in immunocompetent mouse models.
  • Inhibition of tumor growth in preclinical cancer models, notably the 4T1 breast cancer model, where TR75-54.7 administration results in significant tumor regression and increased overall survival of treated mice.
  • Blockade of ligand-induced TNFR2 signaling, which modulates processes such as immunoregulation, cell proliferation, apoptosis, and inflammation.
  • Combination immunotherapy studies: TR75-54.7 is frequently used alongside other agents, such as anti-CD25 (PC61) or checkpoint inhibitors like anti-PD-L1, to evaluate synergistic or additive effects on tumor rejection and survival.
  • Generation of tumor-specific immunity: TR75-54.7 treatment has resulted in long-term protection against subsequent challenge with the same tumor cells, indicating robust tumor-specific memory responses.
  • As a functional blocking antibody, TR75-54.7 is applied for mechanistic studies of TNFR2 signaling in vivo, helping to clarify its role in regulatory T cell function, hematopoiesis, and inflammatory disease models.

Additional in vivo uses:

  • Flow cytometry to track TNFR2+ cells and immune subsets following antibody administration.
  • ELISA capture antibody for quantifying TNFR2 or monitoring treatment effects.

These applications make TR75-54.7 an essential tool in immuno-oncology and immunoregulation studies in mice, especially for dissecting TNFR2's role in tumor immunity and therapeutic antibody development.

Commonly used antibodies or proteins in conjunction with TR75-54.7 (an anti-TNFR2/CD120b antibody) include:

  • TR75-32.4: This antibody targets the same molecule (TNFR2) and is frequently paired with TR75-54.7 in assays such as ELISA, where TR75-54.7 serves as the capture antibody and TR75-32.4 (often biotinylated) as the detection antibody.
  • PC61: An anti-CD25 (IL-2Rα) monoclonal antibody widely used in immunology research, notably for regulatory T cell (Treg) depletion experiments in tumor immunology. Studies often combine TR75-54.7 with PC61 to investigate synergistic effects on Treg cell targeting and antitumor immunity.
  • Anti-PD-L1 (B7H1) antibody (Clone 10F.9G2): Used in combination with TR75-54.7 in cancer immunotherapy research to study co-blockade of immune checkpoints.
  • Secondary antibodies: Such as biotinylated anti-Armenian hamster IgG or streptavidin-PE (SAv-PE), are used for detection when primary antibodies like TR75-54.7 are unconjugated.
  • Cytokines and Ligands: TNF-α and LT-α (ligands for TNFR2) may be added in vitro to stimulate or challenge cells prior to blockade with TR75-54.7.

Typical experiments in the literature using TR75-54.7 frequently employ the following combinations:

  • TR75-54.7 (capture) + TR75-32.4 (detector) for ELISA.
  • TR75-54.7 + PC61 for functional Treg studies and tumor models.
  • TR75-54.7 + anti-PD-L1 (10F.9G2) for combinatory immunotherapy.

These pairings are often chosen based on the experimental goal (e.g., flow cytometry, ELISA, in vivo Treg depletion, or combined checkpoint blockade in tumor models).

Clone TR75-54.7 is a monoclonal antibody that targets mouse Tumor Necrosis Factor Receptor Type II (TNFR2), also known as CD120b or p75. Key findings from its citations in scientific literature are as follows:

Key Findings

  1. TNFR2 Agonism vs. Antagonism: TR75-54.7 acts as a TNFR2 agonist when cross-linked in vitro, promoting cell proliferation and NF-κB activation. However, it is also characterized as a functional blocking antibody, suggesting it can block ligand-induced receptor signaling under certain conditions.

  2. Antitumor Effects: The antibody has been shown to inhibit tumor growth more effectively than CD25 antagonistic antibodies in certain mouse models. It enhances survival in tumor-bearing mice and is particularly effective when combined with other therapies like CD25 blockade.

  3. Mechanism and Relevance: TNFR2 is involved in various biological processes, including immunoregulation, apoptosis, and cell differentiation. The receptor's activation can lead to NF-κB signaling, which plays a role in inflammation and immune responses.

  4. Therapeutic Potential: The combination of anti-TNFR2 antibodies with other immunotherapies, such as anti-PD-L1, has been explored for enhanced antitumor effects.

  5. Experimental Use: TR75-54.7 is used in research for detecting mouse TNFR2 by flow cytometry and ELISA, acting as a capture antibody when paired with other antibodies.

Dosing regimens for clone TR75-54.7 (anti-mouse TNFR2) vary by mouse strain, tumor type, and experimental protocol, with specific details reported for FVB/n, C57BL/6j, NSG, Balb/c, CT26, and JAK2+/VF models.

  • Strain and Tumor Model Variation:

    • Dosing is adapted for mouse strain (e.g., FVB/n, C57BL/6j, NSG, Balb/c) and the type and location of tumor engraftment.
    • For pancreatic cancer models, commonly used strains are FVB/n, C57BL/6j, and NSG, with protocols adjusted for tumor site and burden.
    • In a 4T1 breast cancer model using Balb/c mice, TR75-54.7 was given via intraperitoneal injection before tumor cell inoculation.
    • For colorectal cancer (CT26) in immunocompetent mice, TR75-54.7 was administered i.p. (intraperitoneally) at 100 μg per injection on days 11, 14, and 18 after tumor engraftment.
  • Hematological Malignancy/Inflammation Model:

    • In a myeloproliferative neoplasm (JAK2+/VF mice), dosing was 5 mg/kg body weight twice a week for 3 weeks by i.p. injection.
  • General Considerations:

    • Experimenters select mouse strain and adjust dose frequency, route (often i.p.), and concentration to optimize for tumor type, immunological context, and desired antitumor effect.
    • Reported regimens range from 100 μg/injection (for tumor inhibition studies) to 5 mg/kg twice weekly (for inflammatory disease models).
    • Dosing is typically started before or after tumor cell implantation depending on study goals (prevention vs. treatment).
  • Combination Treatments:

    • TR75-54.7 is sometimes co-administered with antibodies targeting other immune regulators (e.g., anti-CD25 PC61) or checkpoint inhibitors, further influencing dosing schedules and outcomes.

Key regimen examples:

Mouse ModelDose/AmountFrequencyRouteDisease ContextReference
CT26 colorectal (BALB/c)100 μg/injectionDays 11, 14, 18 post-tumori.p.Tumor inhibition
4T1 breast (Balb/c)Protocol details not numerically specified; administered before tumor inoculationNot detailedi.p.Tumor inhibition
JAK2+/VF (hematologic)5 mg/kg/injectionTwice weekly, 3 weeksi.p.Inflammatory/MPN model
Pancreatic (FVB/n, C57BL/6j, NSG)Protocols vary; strain, tumor, engraft site–dependentVariesi.p.Pancreatic cancer

Regimens should always be tailored based on mouse strain, tumor type, disease context, and desired experimental outcome. Always consult published protocols for your specific model; adjust dose and schedule as needed for immunological or pharmacokinetic differences across strains.

References & Citations

1. Zuckerman, KS. et al. (1998) Cancer Res. 58:2217.
2. Sheehan, KC. et al. (1995) J. Exp. Med. 181:607.
B
Elisa Sandwich Protocol
Flow Cytometry
in vivo Protocol
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.